Antimalarial resistance threatens global malaria control efforts. The World Health
Organization (WHO) recommends routine antimalarial efficacy monitoring through a …

Background This open-label, randomized study evaluated efficacy and safety of artemether-
lumefantrine (AL) and dihydroartemisinin-piperaquine (DP) in treatment of uncomplicated …

Background Artemether-lumefantrine (AL) was adopted as first-line treatment for
uncomplicated malaria in Kenya in 2006. Monitoring drug efficacy at regular intervals is …

Objectives To compare the efficacy and safety of artemether-lumefantrine (AL) and
dihydroartemisinin-piperaquine (DP) for treating uncomplicated falciparum malaria in …

Abstract Background Malaria in Zambia remains a public health and developmental
challenge, affecting mostly children under five and pregnant women. In 2002, the first-line …

Abstract Background The Angolan government recommends three artemisinin-based
combinations for the treatment of uncomplicated Plasmodium falciparum malaria: artemether …

Background. Artemisinin-based combination therapies are now widely recommended as first-
line treatment for uncomplicated malaria. However, which therapies are optimal is a matter …

Background Artemether-lumefantrine (AL) was introduced for treatment of uncomplicated
malaria in Guinea-Bissau in 2008. Malaria then resurged and recurrent malaria after …

Background Triple antimalarial combination therapies combine potent and rapidly cleared
artemisinins or related synthetic ozonides, such as arterolane, with two, more slowly …

Background Prospective efficacy monitoring of anti-malarial treatments is imperative for
timely detection of resistance development. The in vivo efficacy of artesunate-amodiaquine …